Needham & Company Downgrades Spectranetics (SPNC) to Buy
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Needham & Company downgraded Spectranetics (NASDAQ: SPNC) from Strong Buy to Buy with a price target of $27.00 on valuation.
Analyst Mike Matson commented, "We hosted SPNC's CEO, Scott Drake, and COO, Shar Matin, for investor meetings last week. Management was upbeat about Stellarex's ability to take share in the drug-coated balloon (DCB) market and SPNC's ability to sustain strong growth in the base Vascular Intervention business and we come away feeling more positive about the prospects for both. However, we downgrade SPNC to Buy from Strong Buy given its valuation."
Shares of Spectranetics closed at $24.01 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham & Company Raises Price Target on II-VI, Inc. (IIVI) Ahead of 1Q Release
- H.C. Wainwright Downgrades Vertex (VRTX) to Neutral
- BMO Capital Raises Price Target on ManpowerGroup (MAN) Following 3Q Surprise
Create E-mail Alert Related CategoriesAnalyst Comments, Downgrades
Related EntitiesNeedham & Company
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!